Lack of Association Between Glucose Homeostasis and Immune Checkpoint Inhibitor Outcomes: A Retrospective Institutional Review.
1/5 보강
[BACKGROUND/OBJECTIVES] Immune checkpoint inhibitors (ICIs) have revolutionized outcomes for patients with melanoma.
APA
Justice J, Burnette H, et al. (2025). Lack of Association Between Glucose Homeostasis and Immune Checkpoint Inhibitor Outcomes: A Retrospective Institutional Review.. Cancers, 17(19). https://doi.org/10.3390/cancers17193230
MLA
Justice J, et al.. "Lack of Association Between Glucose Homeostasis and Immune Checkpoint Inhibitor Outcomes: A Retrospective Institutional Review.." Cancers, vol. 17, no. 19, 2025.
PMID
41097756 ↗
Abstract 한글 요약
[BACKGROUND/OBJECTIVES] Immune checkpoint inhibitors (ICIs) have revolutionized outcomes for patients with melanoma. As such, it is important to understand factors that may influence response as well as toxicity to these therapies. Impaired glucose control is often a sign of pathologic inflammation and may alter immune system regulation, but it is unclear whether glucose control impacts patients with melanoma on ICIs.
[METHODS] After reviewing patients with melanoma treated with ICIs at our institution between 2014 and 2024, we assessed whether longitudinal glucose control is associated with patient outcomes (response, progression-free survival, overall survival, and treatment toxicity) during ICI therapy.
[RESULTS] There was no significant difference in baseline glucose values between responders and non-responders (102.5 vs. 106.0, = 0.093). Having a baseline glucose over 200 or any glucose over 200 was not significantly associated with response ( = 0.79, = 0.20), progression-free survival ( = 0.64, = 0.45), overall survival ( = 0.56, = 0.36), or toxicity ( = 0.29, = 0.11). Although a diagnosis of diabetes mellitus was not significantly associated with response ( = 0.84), progression-free survival ( = 0.12), or toxicity ( = 0.11), it was associated with improved overall survival ( = 0.0034) in the small number of patients with diabetes.
[CONCLUSIONS] Overall, we observed that glucose control was not strongly associated with efficacy or toxicity in patients treated with ICIs.
[METHODS] After reviewing patients with melanoma treated with ICIs at our institution between 2014 and 2024, we assessed whether longitudinal glucose control is associated with patient outcomes (response, progression-free survival, overall survival, and treatment toxicity) during ICI therapy.
[RESULTS] There was no significant difference in baseline glucose values between responders and non-responders (102.5 vs. 106.0, = 0.093). Having a baseline glucose over 200 or any glucose over 200 was not significantly associated with response ( = 0.79, = 0.20), progression-free survival ( = 0.64, = 0.45), overall survival ( = 0.56, = 0.36), or toxicity ( = 0.29, = 0.11). Although a diagnosis of diabetes mellitus was not significantly associated with response ( = 0.84), progression-free survival ( = 0.12), or toxicity ( = 0.11), it was associated with improved overall survival ( = 0.0034) in the small number of patients with diabetes.
[CONCLUSIONS] Overall, we observed that glucose control was not strongly associated with efficacy or toxicity in patients treated with ICIs.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- SLC2A1 tumour-associated macrophages spatially control CD8 T cell function and drive resistance to immunotherapy in non-small-cell lung cancer.
- Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study.
- Chalcone-containing dual-targeting PD-L1/tubulin small molecules: a novel approach for cancer immunotherapy.
- Immune Checkpoint Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation: Safety Under an Immunosuppression-Preserving Strategy.
- Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study.
- CRISPR/Cas9 Screening Reveals that UBE2L3 Modulates Autophagic Flux through TSC2 Ubiquitination and Potentiates PD-1 Blockade in Triple-Negative Breast Cancer.